Brief: Catalyst Pharmaceuticals Q2 Revenue USD 146.6 Million Vs. IBES Estimate USD 140.6 Million

Catalyst Pharmaceuticals

06/08/2025 21:13

Overview

Catalyst Q2 2025 revenue rises 19.4% yr/yr, beating analyst expectations, per LSEG data

Adjusted EPS for Q2 exceeds estimates, reflecting strong operational performance

AGAMREE Q2 net product revenue up 212.9% yr/yr, FYCOMPA declines due to generic entry

Outlook

Catalyst reaffirms 2025 revenue guidance of $545 mln to $565 mln

Company expects broad-based growth and sustained demand in 2025

Catalyst anticipates impact from generic competition on FYCOMPA

Company highlights strong cash position to support strategic initiatives

Result Drivers

FIRDAPSE DEMAND - Despite temporary insurance processing impact, FIRDAPSE net revenue grew 9.7% YoY, reflecting strong demand

AGAMREE ADOPTION - AGAMREE revenue surged 212.9% YoY, driven by accelerating physician adoption post-launch

FYCOMPA GENERIC IMPACT - FYCOMPA revenue decreased 6.0% YoY due to generic competition following loss of exclusivity

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$146.60 mln
$140.60 mln (8 Analysts)
Q2 Adjusted EPS
Beat
$0.68
$0.39 (5 Analysts)
Q2 Adjusted Net Income
$86.40 mln
Q2 Net Income
$52.10 mln
Q2 Operating Income
$66.30 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Catalyst Pharmaceuticals Inc is $33.00, about 32.7% above its August 5 closing price of $22.22

The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 16 three months ago

Press Release: ID:nGNX2y5f7L

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)